← SynDRA
TELATINIB
SynDRA canonical compound SYN0029840 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | KDR |
|---|
| Mechanism of action | VEGFR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- KIT INHIBITOR
- PDGFR inhibitor
- VEGFR inhibitor
- Stem cell growth factor receptor inhibitor
- PDGFRB INHIBITOR
- Platelet-derived growth factor receptor beta inhibitor
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- FLT4 INHIBITOR
- Vascular endothelial growth factor receptor 3 inhibitor
- PDGFR tyrosine kinase receptor inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MAP3K20
- ILK
- AAK1
- PAK6
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PASK
- PAK4
- PIM1
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- PHKG2
- PIM2
- NLK
- PRKACB
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACA
- PIP4K2C
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- NQO2
- NEK9
- PRKCI
- MARK2
- MAP4K3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- BAY 57-9352
- BAY-579352
- Bay 57-9352
- BAY-57-9352
- Telatinib (BAY 57-9352)
- Telatinib [INN]
- 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide
- 4-[[4-(4-Chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methyl-pyridine-2-carboxamide
- BAY 579352
- BAY57-9352
- CHEMBL2079588
- 18P7197Q7J
- 4-(((4-((4-chlorophenyl)amino)furo[2,3-d]pyridazin-7-yl)oxy)methyl)-N-methylpicolinamide
- 4-((4-(4-chlorophenylamino)furo[2,3-d]pyridazin-7-yloxy)methyl)-N-methylpicolinamide
- UNII-18P7197Q7J
- TELATINIB [WHO-DD]
- MLS006010950
- SCHEMBL1250560
- Bay 57-9352 (Telatinib)
- GTPL10476
- Telatinib - BAY 57-9352
- DTXSID70954809
- EX-A007
- BCPP000050
- HMS3655F14
- ZINC590964
- BCP02409
- BAY579352
- BDBM50399538
- MFCD18251453
- NSC776017
- NSC800944
- s2231
- AKOS015909525
- CCG-264951
- CS-3722
- DB15393
- EX-8672
Look up TELATINIB in the interactive SynDRA portal →